A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

Find Injective (INJ) price predictions for 2025, 2026 and 2030. Discover key investment factors, risks and analyst forecasts for this leading DeFi blockchain.

MSD and Moderna start a third phase 3 trial of their V940 cancer vaccine, their second in early-stage lung cancer.